Mark Lowdell is Director of the Centre for Cell, Gene & Tissue Therapeutics at the Royal Free Hospital and Professor of Cell & Tissue Therapy at UCL. He is a world-leader in the development of cell and tissue medicines for immunotherapy and transplantation and is an MHRA Qualified Person for release of Advanced Therapy Medicinal Products, for use in clinical trials. He has been responsible for the development and delivery of multiple cell based therapies and the first GMP-compliant embryonic stem-cell derived product trialled in the UK. He is a founder of Cell Medica Ltd, InMune Bio Inc and Immune Ventures. Mark holds a PhD in clinical immunology from the University of London and fellowships from the Royal College of Pathologists (immunopathology) and the Royal Society of Biology. He is the current Vice President (EU) of the International Society for Cell Therapy.

 Mark Lowdell is Director of the Centre for Cell, Gene & Tissue Therapeutics at the Royal Free Hospital and Professor of Cell & Tissue Therapy at UCL. He is a world-leader in the development of cell and tissue medicines for immunotherapy and transplantation and is an MHRA Qualified Person for release of Advanced Therapy Medicinal Products, for use in clinical trials. He has been responsible for the development and delivery of multiple cell based therapies and the first GMP-compliant embryonic stem-cell derived product trialled in the UK. He is a founder of Cell Medica Ltd, InMune Bio Inc and Immune Ventures. Mark holds a PhD in clinical immunology from the University of London and fellowships from the Royal College of Pathologists (immunopathology) and the Royal Society of Biology. He is the current Vice President (EU) of the International Society for Cell Therapy.